PDUFA dates November 2021: FDA calendar and catalysts.
0 PDUFA dates fell in November 2021. The FDA calendar also recorded 11 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.
PDUFA dates in November 2021
No PDUFA dates are disclosed for this period as of November 16, 2026.
Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months
November 2021: other FDA decisions and filings
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| November 4, 2021 | Byetta (exenatide synthetic) | AZN | Label expansion | — | Approved | openFDA Drugs@FDA |
| November 15, 2021 | Mvasi (bevacizumab-awwb) | AMGN | Label expansion | — | Approved | openFDA Drugs@FDA |
| November 15, 2021 | Ruxience (rituximab-pvvr) | PFE | Label expansion | — | Approved | openFDA Drugs@FDA |
| November 17, 2021 | — | ARMP | FDA approval | — | Approved | SEC Form 10-Q |
| November 17, 2021 | KEYTRUDA® (pembrolizumab) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| November 19, 2021 | Kanuma (sebelipase alfa) | AZN | Label expansion | — | Approved | openFDA Drugs@FDA |
| November 23, 2021 | TPOXX® (tecovirimat) | SIGA | Label expansion | — | Approved | openFDA Drugs@FDA |
| November 23, 2021 | Livtencity (maribavir) | TAK | FDA approval | — | Approved | openFDA Drugs@FDA |
| November 26, 2021 | Pedmark (sodium thiosulfate) | FENC | Complete Response Letter | — | CRL issued | FDA Complete Response Letters |
| November 29, 2021 | YCANTH (cantharidin) | VRCA | NDA/BLA submission | molluscum | Completed | sec_424b |
| November 30, 2021 | Darzalex Faspro (daratumumab and hyaluronidase-fihj) | JNJ | Label expansion | — | Approved | openFDA Drugs@FDA |
November 2021: dated readouts
No events in this view.
Questions
What PDUFA dates are in November 2021?
0 PDUFA dates fell in November 2021. The FDA calendar also recorded 11 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.
Can these dates change?
Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.